Trial Profile
Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2023 Planned End Date changed from 1 Oct 2024 to 1 May 2025.
- 30 Jan 2023 Planned primary completion date changed from 1 Oct 2023 to 1 May 2025.
- 30 Jan 2023 Status changed from recruiting to active, no longer recruiting.